The generalized pustular psoriasis (GPP) Forum 2023
An executive summary of the activities and key takeaways from the GPP Forum 2023
Search
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Risk of parasites in dogs
With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
Ruminant parasite control in a nutshell
An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
Rahul Prasad
Rahul J. Prasad is a Senior Consultant with our Corporate Strategy & Consulting division – a job that suits his passion for data and his love of variety.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
First Translational Medicine Award awarded
The Award recognizes the research that has the highest translational potential
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.